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It has been accepted since the 1990s 
that palliative chemotherapy can 
significantly prolong the survival of 
patients with advanced gastric carci-
noma, compared to supportive care 
alone [1,2]. However, there is con-
troversy over the benef it of salvage 
therapy past second-line due to the 
lack of evidence. Recently, there has 
been renewed interest in salvage che-
motherapy after first- and second-line 
treatments have failed because of the 
prolonged survival time and relatively 
low toxicity of agents.
Many clinicians consider second-
line chemotherapy after failure of 
f irst-line chemotherapy for patients 
with advanced gastric carcinoma 
[3]. Phase II trials and retrospective 
analyses have provided evidence that 
second-line is effective [4]. Recently, 
randomized phase III trials have 
strongly indicated that second line 
or further chemotherapy is more ad-
vantageous than supportive care (Table 
1). A German trial found that irino-
tecan monotherapy improved overall 
survival compared to best supportive 
care [5]. A Korean trial found that 
irinotecan or docetaxel monotherapy 
prolonged overall survival compared 
to best supportive care and there was 
no difference in the treatment ef-
fect of docetaxel and irinotecan (p = 
0.116) [6]. In the 2013 the American 
Society of Clinical Oncology (ASCO) 
Gastrointestinal Cancer Symposium, 
it was reported that docetaxel [7] and 
ramucirumab [8] demonstrated clini-
cal benef it over supportive care in 
two phase III trials. Both agents sig-
nificantly prolonged overall survival 
(Table 1). There is ample evidence to 
support the use of second line treat-
ment in advanced gastric cancer. 
However, the issue of which regimen 
is a standard second-line treatment 
has not been clarified.
Little information concerning the 
survival advantage of third-line che-
motherapy is extant. In a Korean 
phase III trial, the survival benefit in 
the chemotherapy arm was preserved 
in the further chemotherapy group 
(hazard ratio, 0.812; 95% confidence 
interval [CI], 0.450 to 1.464) (Table 1). 
Several retrospective studies pre-
sented the natural history of advanced 
gastric cancer with sequential salvage 
chemotherapy following f irst-line 
treatment [4]. The survival prolonga-
tion by second- and third-line salvage 
chemotherapy indicates its feasibility 
in selected patients.
After failure of first-line chemother-
apy based on platinum and fluoropy-
rimidine, irinotecan, or taxane-based 
regimens have benef ited survival 
and led to the same clinical outcome 
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as salvage chemotherapy in advanced gastric cancer 
patients [4,6]. Based on the lack of cross-resistance 
between irinotecan and taxane, both regimens are 
plausible salvage treatment options. Additionally, it is 
necessary to select patients for salvage chemotherapy 
based on survival predictors including performance 
status, chemotherapy-free interval, response duration, 
metastatic pattern, tumor burden, and serum carcino-
embryonic antigen level [4,6].
Lee and colleagues [9] evaluated the eff icacy and 
toxicity of docetaxel monotherapy, 75 mg/m2 on day 
1 every 3 weeks, in advanced gastric cancer patients 
who did not respond to oxaliplatin with leucovorin 
and 5-f luorouracil (m-FOLFOX-4), or to irinotecan 
with leucovorin and 5-fluorouracil (m-FOLFIRI). This 
retrospective study included thirty three patients and 
reported an overall response of 15%, time to progres-
sion of 2.1 months (95% CI, 1.63 to 2.58), and an overall 
survival time of 4.7 months (95% CI, 3.20 to 6.20). The 
results are comparable to previous reports of the ef-
ficacy of third-line treatment. This study provides im-
portant evidence that docetaxel is a feasible third-line 
therapy regimen after m-FOLFIRI and m-FOLFOX-4 
regimens. A randomized prospective trial could fur-
ther support this conclusion.
Trastuzumab, a molecular target agent, was ap-
proved for HER2 amplif ied gastric cancer patients, 
and other anti-HER2 agents—including lapatinib—
have been evaluated as f irst- or second-line treat-
ments. Furthermore, studies have been performed to 
elucidate biomarkers of chemotherapeutic agents and 
to investigate molecular biological features, includ-
ing genetic and epigenetic profiles [10]. On the basis 
of those outcomes, randomized trials of target agents, 
and molecular biologic markers would facilitate treat-
ment tailored to the individual patient.
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